Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rolf Olav Larsen is active.

Publication


Featured researches published by Rolf Olav Larsen.


Investigational New Drugs | 1990

In vivo and in vitro pharmacokinetics of 4,6-benzylidene-D-glucose (BG) in rats

John Michael Dornish; Rolf Olav Larsen; Per E. Schwarze; Bernt Borretzen; Erik O. Pettersen

SummaryIn vivo pharmacokinetics of 4,6-benzylidene-D-glucose (BG) was investigated in rats following an i.v. bolus injection of 85 mg BG/kg body weight. High performance liquid chromatography (HPLC) was used to characterize and quantitate BG in whole blood or serum samples. It was found that BG rapidly disappeared with a half-life (t1/2)on the order of 10 min. At the same time a metabolite appeared which eluted before the double isomer peaks of BG. It increased in concentration from 0 to 30 min after initial i.v. injection of BG. Thereafter the metabolite was slowly removed or cleared from the animals. The t1/2 of the metabolite calculated from the time of maximum concentration was found to be about 1 h. BG was also metabolized by whole rat blood at 37°C, but on a different time scale in vitro. The t1/2 of BG in the in vitro assays was now about 4 h, as compared to 10 min in vivo. BG was not metabolized in rat plasma or rat serum. In contrast to in vivo data, the metabolite of BG was not reduced upon further incubation, but remained in blood samples with no reduction for at least 24 h. In addition, we found that protein synthesis was inhibited by approximately 50% when isolated rat hepatocytes were incubated with 3.2 mM BG. BG was slowly metabolized by hepatocytes to produce a metabolite indistinguishable (by HPLC) from that found in blood samples. Analysis of the metabolite by combined gas chromatography-mass spectrometric (GC-MS) methods identified it as being 1,3-benzylidene-D-glucitol. An intracellular reduction of BG by aldose reductase is proposed to occur.


Archive | 1991

PHARMACEUTICAL COMPOSITIONS WITH ANIT-CANCER ACTIVITY AND METHOD FOR THE TREATMENT OF CANCER

Reidar Oftebro; Erik O. Pettersen; John Michael Dornish; Bernt Borretzen; Rolf Olav Larsen


Archive | 1991

Acetal derivatives of aromatic aldehydes

Erik O. Pettersen; Rolf Olav Larsen; Bernt Borretzen; John Michael Dornish; Reidar Oftebro


Archive | 1989

Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer sensitive to treatment

Reidar Oftebro; Erik O. Pettersen; John Michael Dornish; Bernt Borretzen; Rolf Olav Larsen


Archive | 1990

Pharmaceutical compositions with anti-cancer activity against carcinoma and method for the treatment of carcinoma

Bernt Borretzen; Rolf Olav Larsen; John Michael Dornish; Reidar Oftebro; Erik O. Pettersen


Archive | 1988

Activity against carcinoma and method for the treatment of carcinoma

Bernt Borretzen; Rolf Olav Larsen; John Michael Dornish; Reidar Oftebro; Erick O. Pettersen


Archive | 1991

Aromatic aldehydes and derivatives and pharmaceutical compositions thereof useful for the treatment of skin diseases and arthritis

Bernt Borretzen; Erik O. Pettersen; Rolf Olav Larsen; John Michael Dornish; Thomas Ramdahl; Reidar Oftebro


Archive | 1989

Pharmaceutical compositions with anti-cancer activity

Reidar Oftebro; Erik O. Pettersen; John Michael Dornish; Bernt Borretzen; Rolf Olav Larsen


Anticancer Research | 1991

Increased effect of benzaldehyde by exchanging the hydrogen in the formyl group with deuterium.

Erik O. Pettersen; Rolf Olav Larsen; Bernt Borretzen; John Michael Dornish; Reidar Oftebro


Anticancer Research | 1992

In vitro modulating effect of the reversible protein synthesis inhibitor zilascorb (2H) on cis-diamminedichloroplatinum (II)-induced cytotoxicity.

Melvik Je; John Michael Dornish; Rolf Olav Larsen; Bernt Borretzen; Reidar Oftebro; Erik O. Pettersen

Collaboration


Dive into the Rolf Olav Larsen's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Per E. Schwarze

Norwegian Institute of Public Health

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge